MUMBAI, India, July 13 -- Intellectual Property India has published a patent application (202617072559 A) filed by Shenzhen Pregene Biopharma Co. , Ltd. on June 11, 2026, for Pd-1 Molecule For Blocking Binding Of Anti-Pd-1 Antibody To Pd-1 Molecule On Cell Surface, And Mutant And Use Thereof.
Inventors include Gao, Quanli; You, Hongqin Wo Publication No; and Chen, Guangyu.
The application for the patent was published on July 10, 2026, under issue no. 28/2026.
Abstract: Provided are a PD-1 molecule for blocking the binding of an anti-PD-1 antibody to a PD-1 molecule on a cell surface, and a mutant and the use thereof. Further provided is a protein molecule, which has 80-100% sequence identity to a wild-type protein as shown in SEQ ID NO: 1. The provided recombinant protein H126 and H134 molecules can competitively bind to an anti-PD-1 antibody drug with the endogenous PD-1 molecule expressed by a T cell, without affecting the binding of PD-1 to an endogenous PD-L1 molecule, thereby restoring the function suppression on activated T cells and alleviating the symptoms of immunotherapy-related adverse events. By means of the protein molecule, a new way of performing clinical treatment of the immunotherapy-related adverse events is provided.
Disclaimer: Curated by HT Syndication.
